Therapeutically, targeting the ApoE cascade through stabilizing the ApoE4 structure (both domain interaction and Trptophan34 sidechain orientation), modulating its lipidation, or mitigating its pathological interactions offers promising avenues for curative interventions in AD [19,25,40,41]. Here, APOE is linked to Alzheimer disease.